Greg and Matias interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health.

In this episode, we discuss:

• How genetic therapies work: addressing underlying causes, not just symptoms
• The opportunities and challenges for genetic therapies for brain health
• Exploring effective delivery of genetic payloads
• Commercial viability and insurance considerations

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions.

Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness).

In this episode, we discuss:

• The science behind transcranial focused ultrasound and its therapeutic potential for mental health
• The risks and considerations involved in using focused ultrasound technology for mental health treatments
• Jay's experience transitioning from academia to founding a mental health technology startup
• The regulatory landscape that Sanmai Technologies will navigate as they bring this novel neurotechnology to market
  
  

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.

Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges.

In this episode, we discuss:

• Different regulatory pathways for neurological devices (510(k), De Novo, PMA)
• FDA's approach to novel neurotechnologies like brain-computer interfaces (BCIs)
• Considerations for invasive vs. non-invasive neurotech devices
• The importance of cybersecurity in neurotechnology
• Common mistakes companies make in the regulatory process and how to avoid them
• The potential future of neurotechnology, including human augmentation and telepathy
  
  

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank and Krotoa by Makropulos